Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent Meets FDA For Review On Anthrax Vaccine
Emergent has announced that it has met with the FDA to review regulatory strategy for the development of recombinant anthrax (rPA) vaccine. Emergent recently submitted rPA Development Plan
Emergent has announced that it has met with the FDA to review regulatory strategy for the development of recombinant anthrax (rPA) vaccine. Emergent recently submitted rPA Development Plan
Dow, a chemical company has unveiled the newly-formed Dow Coatings Materials. Following the acquisition, Dow Coatings Materials provides a wide range of chemistries and support across many different
Dow has announced that it has launched a new business and innovation hub in the Asia Pacific region, the Shanghai Dow Center. Occupying more than 100,000 square meters,
Eli Lilly has announced that the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) has voted that Zyprexa (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute
Emergent has announced that BioThrax (Anthrax Vaccine Adsorbed) has been granted a shelf life extension from 3 to 4 years by the FDA. Based on the approval, Emergent
New Jersey-based Wyeth has announced that the new data from phase-III clinical trials shows that investigational pneumococcal vaccine, Prevenar13, has the potential to provide coverage against the 13
Pfizer has announced that data from two new mid-stage clinical studies of oral JAK-3 inhibitor, CP-690,550, showed statistically significant response, versus placebo for patients with rheumatoid arthritis (RA).
Sanofi-Aventis and Regeneron have announced that advanced ovarian cancer patients with recurrent symptomatic malignant ascites (SMA) receiving aflibercept (VEGF Trap) in a randomized, placebo-controlled Phase 2 study, experienced
Neurim has declared the preliminary results of phase-III study of Circadin 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. Circadinis, a
STAAR has announced that FDA has granted 510(k) clearance for Epiphany Injector System for use with the Affinity Collamer Three-Piece NTIOL and the Elastimide Silicone NTIOL. Epiphany has